Ayuso Miriam, Buyssens Laura, Stroe Marina, Valenzuela Allan, Allegaert Karel, Smits Anne, Annaert Pieter, Mulder Antonius, Carpentier Sebastien, Van Ginneken Chris, Van Cruchten Steven
Comparative Perinatal Development, Department of Veterinary Sciences, University of Antwerp, 2610 Wilrijk, Belgium.
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
Pharmaceutics. 2020 Dec 30;13(1):44. doi: 10.3390/pharmaceutics13010044.
Pharmacotherapy in pediatric patients is challenging in view of the maturation of organ systems and processes that affect pharmacokinetics and pharmacodynamics. Especially for the youngest age groups and for pediatric-only indications, neonatal and juvenile animal models can be useful to assess drug safety and to better understand the mechanisms of diseases or conditions. In this respect, the use of neonatal and juvenile pigs in the field of pediatric drug discovery and development is promising, although still limited at this point. This review summarizes the comparative postnatal development of pigs and humans and discusses the advantages of the juvenile pig in view of developmental pharmacology, pediatric diseases, drug discovery and drug safety testing. Furthermore, limitations and unexplored aspects of this large animal model are covered. At this point in time, the potential of the neonatal and juvenile pig as nonclinical safety models for pediatric drug development is underexplored.
鉴于影响药物代谢动力学和药效学的器官系统及过程的成熟情况，儿科患者的药物治疗具有挑战性。特别是对于最年幼的年龄组以及仅适用于儿科的适应症，新生和幼年动物模型可用于评估药物安全性，并更好地理解疾病或病症的机制。在这方面，尽管目前仍有限，但在儿科药物发现和开发领域使用新生和幼年猪具有前景。本综述总结了猪和人类出生后的发育对比情况，并鉴于发育药理学、儿科疾病、药物发现和药物安全性测试讨论了幼年猪的优势。此外，还涵盖了这种大型动物模型的局限性和未探索的方面。目前，新生和幼年猪作为儿科药物开发非临床安全性模型的潜力尚未得到充分探索。
